Mirum Pharmaceuticals (MIRM) Cash & Equivalents (2018 - 2026)

Mirum Pharmaceuticals has reported Cash & Equivalents for 9 years, with the latest figure at $324.9 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents rose 53.39% year-over-year to $324.9 million; the trailing twelve-month figure through Mar 2026 stood at $324.9 million (up 53.39% YoY), and the FY2025 full-year result was $296.7 million, up 33.08% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $324.9 million, up from $296.7 million in the prior quarter.
• The five-year high for Cash & Equivalents was $324.9 million in Q1 2026, with the low at $49.4 million in Q1 2023.
• Average Cash & Equivalents over 5 years is $233.5 million, with a median of $239.9 million recorded in 2022.
• Year-over-year, Cash & Equivalents slumped 79.4% in 2023 and surged 512.81% in 2024.
• Tracing MIRM's Cash & Equivalents over 5 years: stood at $128.0 million in 2022, then jumped by 123.69% to $286.3 million in 2023, then slipped by 22.14% to $222.9 million in 2024, then soared by 33.08% to $296.7 million in 2025, then grew by 9.51% to $324.9 million in 2026.
• The last three Cash & Equivalents figures came in at $324.9 million (Q1 2026), $296.7 million (Q4 2025), and $282.0 million (Q3 2025), per Business Quant data.

Peer Comparison